FDA Reclassifies UV-C Disinfection and Cardiac Ablation Protection Devices to Class II: A 510(k) Strategy Guide

Device classification decides almost everything about a United States market entry: the evidence you need, the review pathway you use, the time it takes, and the cost. On 10 September 2026, the FDA moved two device types into Class II through final classification orders in the Federal Register. One covers whole room microbial reduction devices, the category that includes the ultraviolet room disinfection systems used in hospitals. The other covers a mechanical device that protects the esophagus during cardiac ablation. For manufacturers in and around these categories, the change is not just administrative. It can open a faster, lower cost route to market.

When the FDA establishes a Class II regulation with special controls, it also creates a predicate pathway. Future devices of the same type can often clear through a 510(k) that shows substantial equivalence, rather than the more demanding de novo or premarket approval route. This guide explains exactly what the FDA classified, what special controls now apply, and how Canadian and international device makers can turn a reclassification into a submission strategy.

Executive summary

On 10 September 2026 the FDA published two device classification final orders. The whole room microbial reduction device is now Class II under 21 CFR 880.6510, defined as a device used to reduce microbial load on medical device surfaces following cleaning and disinfection. The mechanical deviation device for esophageal protection during cardiac ablation is now Class II under 21 CFR 870.5710. Each order sets special controls, meaning the specific testing and labelling a manufacturer must meet. Because a Class II regulation supports the 510(k) pathway, these orders can lower the barrier to market for the affected device types, provided a manufacturer builds a submission that meets the new special controls. Companies should confirm their device's classification, read the special controls closely, and decide whether a 510(k) is now the right route.

What FDA did, in plain terms

What it is. The FDA issued two final orders classifying specific device types into Class II and creating a new regulation for each in Title 21 of the Code of Federal Regulations. Both orders followed the de novo route, which the FDA uses to classify a novel device that has no existing predicate. Once classified, that regulation and its special controls become the reference point for later devices of the same type.

Why it matters. Classification sets the rules of entry. A device with a Class II regulation and an available predicate can usually pursue a 510(k), which is faster and less costly than a de novo or a premarket approval application. For companies building products in these two spaces, the orders reduce uncertainty and can shorten the path to a United States clearance.

What to do. Confirm whether your device fits one of the new regulations, read the special controls in full, and design your testing and labelling to meet them from the start. The two orders are summarised below.

What Class II and special controls mean

The FDA sorts devices into three classes by risk. Class I devices are low risk and mostly need only general controls. Class II devices are moderate risk and need general controls plus special controls, which are device specific requirements the FDA judges necessary to provide reasonable assurance of safety and effectiveness. Class III devices are the highest risk and usually require a premarket approval application supported by clinical evidence.

Special controls are the heart of a Class II regulation. They can include specified performance testing, biocompatibility, electrical safety and electromagnetic compatibility, software verification and validation, sterilization or reprocessing validation, and particular labelling. When a manufacturer files a 510(k) for a Class II device, the submission must show that the device meets the applicable special controls and is substantially equivalent to a legally marketed predicate.

Device one: whole room microbial reduction devices

What it is. The FDA defines a whole room microbial reduction device as a device used to reduce microbial load on medical device surfaces following cleaning and disinfection, now classified in Class II under 21 CFR 880.6510. In practice this category covers automated room treatment systems used in healthcare settings, including many that use ultraviolet, or UV-C, energy. The classification itself is technology neutral, but the special controls make clear it contemplates lamp based systems.

Why it matters. Infection control suppliers who previously faced an uncertain classification now have a defined Class II regulation to build toward. That clarity supports investment and a predictable submission, but it also raises the bar: the special controls set concrete testing expectations that a marketing claim of microbial reduction must now be able to support.

The special controls for these devices include the following categories of evidence.

Device two: esophageal protection during cardiac ablation

What it is. The mechanical deviation device for esophageal protection during cardiac ablation is now Class II under 21 CFR 870.5710. The device uses mechanical means to move the esophagus away from the source of ablation energy during a cardiac ablation procedure, reducing the risk of thermal injury to the esophagus, a rare but serious complication of atrial fibrillation ablation.

Why it matters. A Class II classification for a device used inside a high risk cardiac procedure signals that the FDA believes special controls, rather than premarket approval, can provide reasonable assurance of safety and effectiveness. For device makers, that is a meaningful reduction in regulatory burden compared with a Class III route, though the special controls still call for solid performance evidence.

The special controls for this device focus on performance. They include non-clinical and animal performance testing to characterise the device's mechanical function and safety, along with labelling that supports safe use during the procedure. A manufacturer should expect to demonstrate that the device deviates the esophagus reliably and does not introduce new harms.

Why reclassification matters: the de novo to predicate pathway

The de novo route lets the FDA classify a novel device that has no predicate. It is more work than a 510(k), but less than a premarket approval. Once the de novo grants a Class II classification, the FDA creates a regulation with special controls, and that regulation becomes a predicate for later devices of the same type. The next manufacturer can often file a 510(k) demonstrating substantial equivalence to the special controls rather than starting from scratch. This is how a single reclassification can open a category. For context on the most demanding route, see our guide to the PMA electronic submission process for Class III devices.

To use the new predicate well, a submission should lean on recognized consensus standards wherever possible. Meeting a recognized standard through a declaration of conformity can streamline the special controls testing and reduce the volume of primary data a reviewer must read. Our explainer on FDA recognized consensus standards and the declaration of conformity sets out how Canadian device makers can use this shortcut.

The software and AI angle for Canadian and cross-border makers

Many modern devices, including room disinfection systems, now include software, and a growing share use machine learning. Where software drives or supports a device function, the FDA expects software verification, validation, and hazard analysis as part of the special controls, and machine learning enabled functions raise added questions about change management. Canadian manufacturers building software driven or AI enabled devices should align their United States plan with Health Canada expectations. Our guide to Health Canada's pre-market guidance for machine learning enabled medical devices and the PCCP explains the Canadian side, and a single quality system built for the FDA QMSR and ISO 13485 can support both markets.

Compliance checklist: acting on a Class II reclassification

Work through these steps before you commit to a submission pathway.

• Confirm the classification. Check whether your device fits 21 CFR 880.6510, 21 CFR 870.5710, or another regulation, and record the correct product code.
• Read the special controls in full. List every performance, biocompatibility, software, safety, and labelling requirement in the new regulation.
• Identify a predicate. Determine whether a legally marketed predicate exists so you can decide between a 510(k) and a de novo.
• Plan the testing. Map each special control to a test method and, where possible, to a recognized consensus standard you can declare conformity to.
• Validate the software. Prepare software verification, validation, and hazard analysis, with a change plan for any machine learning functions.
• Draft compliant labelling. Ensure instructions, warnings, and use conditions match the special controls exactly.
• Consider a pre-submission. For any uncertainty on predicate or test methods, a Q-submission meeting with the FDA can confirm the plan before you spend.

Common mistakes to avoid

• Filing under an outdated classification assumption after the regulation has changed, which can trigger a refuse to accept decision.
• Treating a Class II reclassification as a lighter burden and underinvesting in the performance testing the special controls demand.
• Choosing a predicate that is not a good match, which weakens the substantial equivalence argument.
• Overlooking software validation or photobiological safety for lamp based systems, both of which the special controls call out.
• Ignoring the Canadian pathway when the same product will be sold in both markets, then duplicating effort later.

Frequently asked questions

What did FDA reclassify in September 2026?

On 10 September 2026 the FDA classified whole room microbial reduction devices into Class II under 21 CFR 880.6510, and the mechanical deviation device for esophageal protection during cardiac ablation into Class II under 21 CFR 870.5710. Both orders set special controls that define the testing and labelling a manufacturer must meet.

Is a whole room UV-C disinfection device Class I, II, or III?

A whole room microbial reduction device, the category that includes UV-C room disinfection systems used to reduce microbial load on medical device surfaces after cleaning and disinfection, is Class II under 21 CFR 880.6510 as of 10 September 2026. It requires general controls plus the special controls set out in the regulation.

Does a Class II reclassification make market entry easier?

Often yes. A Class II regulation with special controls creates a predicate, which can allow a 510(k) rather than a de novo or a premarket approval. The route is less burdensome, but the device must still meet all the special controls and show substantial equivalence to a suitable predicate.

What are special controls?

Special controls are the device specific requirements the FDA judges necessary to provide reasonable assurance of safety and effectiveness for a Class II device. They can include performance testing, biocompatibility, software validation, electrical safety, and particular labelling. A 510(k) must show the device meets the applicable special controls.

How does this affect a Canadian medical device licence?

Health Canada classifies devices separately from the FDA, so a United States Class II device is not automatically Class II in Canada. A company selling in both markets should confirm the Canadian classification and licence pathway independently, then build one evidence base that can support both submissions where the requirements overlap.

What is the difference between a 510(k) and a de novo?

A 510(k) shows a device is substantially equivalent to a legally marketed predicate. A de novo is used when a novel low to moderate risk device has no predicate, and it results in a new Class I or Class II classification with special controls. Once a de novo creates that regulation, later devices of the same type can often use a 510(k).

How MFLRC can help

MFLRC helps device companies turn a classification change into a clear submission strategy. Our regulatory affairs, licensing, and import and export services confirm the correct classification and pathway, identify a suitable predicate, and plan a 510(k) or de novo that meets the special controls. Our validation services cover the process, software, and packaging validation a submission depends on, and our medical device regulatory support ties United States clearance to a matching Canadian licence strategy so one programme serves both markets.

Not sure whether your device now qualifies for a faster 510(k) after the September 2026 reclassifications? A short classification and pathway review can save months and protect your launch timeline.

Conclusion

The September 2026 reclassifications of whole room microbial reduction devices and the cardiac ablation esophageal protection device are more than housekeeping. Each new Class II regulation defines the special controls a device must meet and creates a predicate that can open a 510(k) route for the whole category. The manufacturers who benefit will be the ones who read the special controls closely, choose the right pathway, and build the testing and labelling to match. Classification is where a submission is won or lost, and these orders have just changed the map for two device types.

Sources and references

• Federal Register: Classification of the Whole Room Microbial Reduction Device (91 FR 57507)
• Federal Register: Classification of the Mechanical Deviation Device for Esophageal Protection During Cardiac Ablation (91 FR 57495)
• FDA: De Novo Classification Request
• FDA: Premarket Notification 510(k)